Table 3.

Relative impact of age‘ of onset, sex, APOE ε4, and disease duration on the presence of each comorbid neuropathological diagnosis

	CAA	LBD, any	LBD, amygdala	TPD-43	HS	AGD	VBI	ATAC	ARTAG
n	132	132	132	132	132	132	132	132	104
Age of onset
Estimate	−0.02	0.00	−0.08	0.10	0.09	0.04	0.10	0.03	0.05
SE	0.02	0.02	0.03	0.03	0.04	0.02	0.02	0.03	0.02
Z	−0.78	−0.27	−2.7	3.58	2.53	2.15	4.38	1.01	2.41
P	0.44	0.79	0.007	0.0003	0.01	0.03	< 0.0001	0.31	0.016
Sex
Estimate	−0.3	0.50	0.86	−0.62	−0.76	−0.48	−0.64	1.12	0.95
SE	0.52	0.38	0.55	0.52	0.71	0.38	0.41	0.61	0.44
Z	−0.58	1.33	1.57	−1.19	−1.06	−1.25	−1.55	1.85	2.16
P	0.56	0.18	0.12	0.23	0.29	0.21	0.12	0.06	0.03
APOE ε4
Estimate	0.7	0.19	−0.02	0.12	0.85	0.62	0.23	0.27	−0.03
SE	0.49	0.36	0.5	0.51	0.77	0.36	0.39	0.51	0.43
Z	1.43	0.54	−0.04	0.24	1.11	1.7	0.58	0.53	−0.08
P	0.15	0.59	0.97	0.81	0.27	0.09	0.56	0.59	0.94
Disease duration
Estimate	−0.01	0.09	0.00	0.10	0.11	0.04	0.16	0.10	0.07
SE	0.07	0.05	0.07	0.07	0.09	0.05	0.06	0.06	0.06
Z	−0.13	1.89	0.03	1.47	1.21	0.73	2.96	1.56	1.2
P	0.90	0.06	0.98	0.14	0.23	0.47	0.003	0.12	0.23

Nine separate logistic regressions were run, one for each neuropathological diagnosis. Age of onset and disease duration are continuous variables, expressed in years; sex is coded as male versus female and APOE ε4 is coded as ε4 carrier versus non-carrier. Positive estimates (i.e. log odds) represent a higher prevalence of the neuropathological finding in patients with older age of onset, males, APOE ε4 carriers, and in patients with longer disease duration. SE= standard error; TDP-43= TDP-43 proteinopathy; VBI = vascular brain injury.